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It is  established  that  (1)  subclinical  Bordetella  pertussis  colonization  of  the  nasopharynx  persists  in  highly
vaccinated  populations,  and  (2)  B. pertussis  toxin  is  a potent  adjuvant  that,  when  co-administered  with
neural antigens,  induces  neuropathology  in experimental  autoimmune  encephalomyelitis,  the principle
animal  model  of  multiple  sclerosis.  Building  on  these  observations  with  supporting  epidemiologic  and






are  innocuous  to  hosts,  B. pertussis  colonization  is an important  cause  of  multiple  sclerosis.
© 2015  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
For more than 50 years, Bordetella pertussis (BP) and BP toxin
BPTOX) have served as laboratory adjuvants to induce sensitiza-
ion to co-localized neural antigens in experimental autoimmune
ncephalomyelitis (EAE), the principle animal model of multiple
clerosis (MS) (Levine and Wenk, 1961). The use of bacterial adju-
ants in EAE is described in thousands of publications and EAE
ecapitulates salient features of MS,  including central nervous sys-
em (CNS) inﬂammation, demyelinated plaques, and disruption
f the blood–brain barrier (BBB). Yet, a widely accepted environ-
ental trigger for MS  remains elusive. Given that nasopharyngeal
ubclinical BP colonization (SCBPC) is well-documented in highly
P-vaccinated populations (Zhang et al., 2014; Ward et al., 2005),
e propose that BP and BPTOX, beyond their role as adjuvants in ani-
al  models of MS,  are actual human neuropathogens. We  review
Abbreviations: SCBPC, subclinical Bordetella pertussis colonization; EAE, experi-
ental autoimmune encephalomyelitis; BP, Bordetella pertussis; BPTOX, Bordetella
ertussis toxin; MS,  multiple sclerosis; CNS, central nervous system; BBB,
lood–brain barrier; wPV, whole-cell pertussis vaccine; aPV, acellular pertussis vac-
ine.
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.0/).epidemiologic and biologic evidence supporting the hypothesis
that SCBPC is an important cause of MS.
MS is a heterogeneous autoimmune demyelinating disease of
the CNS with concordance rates in monozygotic twins of 5.9–50%
(Willer et al., 2003), indicating signiﬁcant environmental causation.
BP is a Gram-negative bacterium that secretes biologically active
toxins and causes whooping cough (acute clinical BP). Subclinical
BP colonizing infections are here deﬁned as asymptomatic or mild
infections (e.g., transient cough, rhinorrhea) that elicit minimal or
no BP-directed host immunity, and thereby allow unopposed BP
toxin activity in a host. To illustrate the relationship between BP




The most striking MS-related epidemiologic phenomenon of the
last century was  the MS  epidemic in the Faroe Islands during, and
immediately after, World War  II (WWII). This outbreak was  ele-
gantly investigated by Kurtzke, who  speculated that “MS  is the
rare late outcome of a speciﬁc but unknown infectious disease of
adolescence and young adulthood” (Kurtzke, 1993). While others
have suggested an MS-BP link (Fiore, 2003), we  propose that, more
precisely, adjuvant-induced neural sensitization by co-localized
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asopharyngeal BP colonization is the primary BP-mediated cause
f MS.
Before 1920, Faroese pertussis outbreaks recurred every 5–6
ears, stimulating BP-speciﬁc systemic and mucosal immunity,
onsistent with clinical studies (Long et al., 1990; Wendelboe et al.,
005), and primate studies demonstrating that acute clinical BP
owers mucosal BP colonization upon reexposure (Warfel et al.,
014). We suggest that the absence of documented MS  in the Faroes
uring this period (Kurtzke, 1993) was due to repeated, likely
nrecognized, BP infections which induced protective mucosal
mmunity (latent BP immunization) thereby limiting subclinical BP
olonization. In addition, regular subclinical or high-dose BP and
PTOX exposure may  have suppressed autoimmunity by inducing
-regulatory cells (Tregs) and anti-inﬂammatory cytokines TGF-
 and IL-10, as demonstrated in rodents (Weber et al., 2010).
otably, suppression of EAE has been demonstrated via pre-
reatment with BP (Lehmann and Ben-Nun, 1992). Faroese BP
pidemiology changed in the 1920s when whole-cell pertussis
accination (wPV) studies immunized nearly 80% of those eligi-
le (Madsen, 1933). These trials decreased BP disease rates, which
e submit reduced individual BP exposure and latent immuniza-
ion, thus diminishing Faroese mucosal BP immunity. Importantly,
ntramuscular wPV does not induce protective mucosal immunity
Warfel et al., 2014; Mills, 2001). By WWII, waning immunity,
ccurring at 4–12 years for wPV and 3.5–20 years for natural immu-
ity (Wendelboe et al., 2005), would have raised the risk for BP
olonization.
From 1940 to 1945, 1000–7000 British troops occupied the
aroes (Kurtzke, 1993), an isolated archipelago with <30,000 inhab-
tants. Since Britain did not nationalize BP vaccination until 1957,
 relatively high rate of BP carriage is expected among troops,
hemselves protected against BP colonization effects by acquired
mmunity from recurrent BP exposures at home. As asymptomatic
P carriage is transmissible (Long et al., 1990; Warfel et al., 2014),
e propose that British soldiers re-introduced BP to a popula-
ion rendered susceptible to BP colonization by lapsed mucosal BP
mmunity after the 1920s wPV trials. Without natural or vaccine-
nduced mucosal BP immunity, the Faroese were susceptible to BP
ransmission from British soldiers—a perfect storm for an SCPBC
nd MS epidemic.
The ﬁrst recorded case of MS  in a native-born Faroese resident
ccurred in 1943, heralding an epidemic peaking two years later
Kurtzke, 1993). Soldiers departed in 1945 and the incidence of
S rapidly dropped off by 1950. Faroese living closest to British
arracks had the highest risk of MS  (Kurtzke, 1993).
.2. Case 2
Global MS  rates exhibit an equatorial gradient: the further
rom the equator, the greater the MS  risk. We  propose that het-
rogeneous global risks for MS  parallel heterogeneous global BP
accination rates, as vaccination inﬂuences BP incidence, individ-
al BP exposure, latent mucosal BP immunization, and thus BP
olonization rates. In the WHO-deﬁned African region, where ini-
ial pertussis vaccination series coverage was 5% in 1980, 52% in
000 and 72% in 2012 (when US rates were 96%, 94% and 96%
espectively) (WHO, 2014), MS  incidence has been low. In sev-
ral African nations from 1960 to 1986, the unweighted mean for
S per 100,000, derived from 8 prevalence studies, was  8 (range
–15), while the mean from 9 US surveys from 1970 to 1985 was
2 (range 9–160) (Rosati, 2001). We  suggest that low African BP
accination rates lead to high individual BP exposure, high rates of
atent immunization and mucosal BP immunocompetence among
dolescents and adults, and therefore to lower BP colonization and
S rates. In contrast, high US vaccination rates lead to low indi-
idual rates of BP exposure, low rates of latent immunization andlogy 221 (2016) 512–515 513
mucosal BP immunocompetence, and to higher BP colonization and
MS rates. We  propose that the equatorial MS  gradient reﬂects a BP
vaccination and SCBPC gradient.
The higher risk for MS  in the US correlates with, but is not held
to be directly caused by, wPV and acellular pertussis vaccination
(aPV), which decrease acute clinical BP risk, but do not induce pro-
tective mucosal immunity, preclude subclinical BP infection (Zhang
et al., 2014; Ward et al., 2005; Warfel et al., 2014) or prevent
transmission (Long et al., 1990; Warfel et al., 2014). Subclinical
BP colonization (not wPV, aPV or acute clinical BP) is proposed to
directly increase MS  risk.
2.3. Case 3
American schoolteachers and healthcare workers are at
increased risk for symptomatic and asymptomatic BP infection (De
Serres et al., 2000; Wright et al., 1999). Government data indi-
cate increased MS  mortality among elementary and secondary
school teachers, compared with all other professional occupations
(proportional MS  mortality: 161%, p < 0.0001), which persists after
adjustment for gender, race and age (Walsh and DeChello, 2001).
Increased MS  risk among health technicians and nurses’ aides has
also been demonstrated (Walsh and DeChello, 2001). Finally, the
2:1 female:male incidence ratio of MS  mirrors the 2:1 female:male
ratio of adult pertussis (De Serres et al., 2000).
3. Biologic evidence
There is substantial biologic plausibility for subclinical BP colo-
nization as a cause of MS.  BP colonization is common in children,
adolescents, and adults (Zhang et al., 2014; Ward et al., 2005).
BP colonizes nasopharyngeal ciliated epithelium, co-localizing BP
with neural antigens such as terminal olfactory nerves. Olfactory
tract inﬂammation and demyelination are common in MS,  sup-
porting co-localized adjuvant-induced sensitization (De Luca et al.,
2014).
Further, BPTOX is a potent exotoxin adjuvant that promotes
autoimmunity in EAE, inducing IL-6-dependent IL-17 producing
T-cells, and reducing Foxp3 + CD4 + CD25 + Tregs, consistent with
MS (Chen et al., 2006, 2007; Hofstetter and Forsthuber, 2002;
Hofstetter et al., 2007). In EAE, neuroantigen-speciﬁc T cells are
activated and propagated (Ben-Nun et al., 1981). BPTOX stimulates
clonal expansion of Th1 and Th17 neuroantigen-speciﬁc T cells, and
increases production of immunoglobulins targeted to co-localized
antigens (Hofstetter and Forsthuber, 2002; Hofstetter et al., 2007;
Ryan et al., 1998). BPTOX also activates antigen presenting cells
(APCs) and effector CD8+ T cells, which are active in MS (Hofstetter
and Forsthuber, 2002; Murphey et al., 2011). In EAE, BPTOX recruits
Th1 cells to the CNS, and, activated by myelin-derived peptide,
induces adhesion of leukocytes to cerebrovascular endothelium
while increasing BBB permeability (Kerfoot et al., 2004).
While spontaneous EAE may  be induced in transgenic models
that circumvent intrinsic autoimmune regulation, most models,
including adoptive transfer EAE (Ben-Nun et al., 1981), require a
bacterial adjuvant to activate and propagate the effector T cells that
ultimately lead to neuropathology (Gold et al., 2006). The impor-
tance of BPTOX in MS  modeling is highlighted by the fact that when
neural antigens are introduced without BPTOX or other adjuvant,
EAE is prevented, but when co-administered with BPTOX, EAE is
induced (Hofstetter and Forsthuber, 2002).4. Discussion
We hypothesize that BP and BPTOX, co-localized at the nasopha-
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omology to neural antigens (Epstein Barr Virus, human herpes
irus 6) (Sospedra and Martin, 2006), facilitate host sensitization to
eural tissue. Subsequent autoimmune responses to neural targets
an then precipitate BP-mediated neuropathology consistent with
S.  In addition, BP may  promote EAE and MS  through non-adjuvant
ffects. For example, BPTOX-induced histamine sensitization, which
an lead to compromised vascular endothelial integrity, is con-
rolled by the Histamine receptor H1 (H1R) gene which has an
stablished role in EAE susceptibility (Ma  et al., 2002). Upregulation
f H1R has been identiﬁed in chronic MS  plaques in humans (Lock
t al., 2002) and it is now established that the H1R gene is actually
he Bordetella pertussis histamine sensitization (Bphs) gene.
Bradford Hill causality criteria (Hill, 1965) support subclini-
al BP colonization as a cause of MS.  The SCPBC-MS association
xhibits a biologic gradient: globally, the risk for BP coloniza-
ion and MS  reﬂects an equatorial BP vaccination gradient; locally,
aroese living closest to British soldiers were at higher MS  risk.
he association is strong with 161% proportional MS  mortality in
eachers, a group at increased risk for BP colonization. The cor-
elation is consistent across populations and time such as the
aroes during WWII  and the US and Africa in recent decades. The
elationship is temporally logical as the introduction of BP pre-
eded MS  in the Faroes as it often does in EAE. Our hypothesis
s analogous to disease models accepted as causal. For example,
elicobacter pylori causes peptic ulcer disease and parallels BP in
S:  H. pylori also colonizes epithelium (gastric epithelium), caus-
ng disease through the release of toxins and by eliciting immune
esponses (Suerbaum and Michetti, 2002). There is evidence for bio-
ogical coherence and plausibility, including the ability of BPTOX to
ctivate APCs, stimulate neuroantigen-speciﬁc T cells, and increase
BB permeability consistent with MS.  Perhaps most striking, the
ypothesis is supported by 50 years of EAE experiments: BP and
PTOX are potent adjuvants used in the principle animal model of
S.
A half-century ago Poskanzer suggested that “The epidemiologi-
al features of multiple sclerosis are compatible with the hypothesis
hat the clinical illness may  be an occasional manifestation of a
idespread subclinical infection” (Poskanzer et al., 1963). With
ocumentation that BP, a potent adjuvant, frequently colonizes
he human nasopharynx, particularly in highly vaccinated popula-
ions, the progression from BP-induced animal modeling of MS  to
nvestigation of the role of BP in human neuropathology seems war-
anted. EAE models using intranasal co-localization of BP and neural
ntigens for sensitization protocols, SCBPC surveillance of cohorts
ollowed for MS  onset, screening for olfactory tract BP-PCR in clin-
cally isolated syndromes which frequently progress to MS,  and BP
olonization eradication studies with MS  as an outcome measure,
ay  one day test the hypothesis that subclinical BP colonization is
n important, previously unidentiﬁed, cause of MS.
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